NeoStem Inc. (NBS) Inks Collaborative Agreement with ImmuneRegen (IRBS) to Advance Adult Stem Cell Technology
NeoStem Inc., an international biopharmaceutical company with operations in the U.S. and China, has entered into a collaborative research agreement with ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR BioSciences Holdings Inc. (IRBS.OB). The companies will work together to develop an advanced, adult human stem cell product. Per the agreement, NeoStem will observe and analyze the effects of ImmuneRegen's lead drug candidate Homspera(R) in combination with NeoStem's VSEL(TM) technology. NeoStem provides adult stem cell banking services and is pursuing further research and development of adult stem cell therapies for regenerative purposes in the U.S. and China. The agreement will…